| Literature DB >> 31653683 |
Afam A Okoye1,2, Maren Q DeGottardi1,2, Yoshinori Fukazawa1,2, Mukta Vaidya1,2, Chike O Abana1,2, Audrie L Konfe1,2, Devin N Fachko1,2, Derick M Duell1,2, He Li1,2, Richard Lum1,2, Lina Gao3, Byung S Park3, Rebecca L Skalsky1,2, Anne D Lewis2, Michael K Axthelm1,2, Jeffrey D Lifson4, Scott W Wong1,2, Louis J Picker5,2.
Abstract
Although IL-15 has been implicated in the pathogenic hyperimmune activation that drives progressive HIV and SIV infection, as well as in the generation of HIV/SIV target cells, it also supports NK and T cell homeostasis and effector activity, potentially benefiting the host. To understand the role of IL-15 in SIV infection and pathogenesis, we treated two cohorts of SIVmac239-infected rhesus macaques (RM; Macaca mulatta), one with chronic infection, the other with primary infection, with a rhesusized, IL-15-neutralizing mAb (versus an IgG isotype control) for up to 10 wk (n = 7-9 RM per group). In both cohorts, anti-IL-15 was highly efficient at blocking IL-15 signaling in vivo, causing 1) profound depletion of NK cells in blood and tissues throughout the treatment period; 2) substantial, albeit transient, depletion of CD8+ effector memory T cells (TEM) (but not the naive and central memory subsets); and 3) CD4+ and CD8+ TEM hyperproliferation. In primary infection, reduced frequencies of SIV-specific effector T cells in an extralymphoid tissue site were also observed. Despite these effects, the kinetics and extent of SIV replication, CD4+ T cell depletion, and the onset of AIDS were comparable between anti-IL-15- and control-treated groups in both cohorts. However, RM treated with anti-IL-15 during primary infection manifested accelerated reactivation of RM rhadinovirus. Thus, IL-15 support of NK cell and TEM homeostasis does not play a demonstrable, nonredundant role in SIV replication or CD4+ T cell deletion dynamics but may contribute to immune control of oncogenic γ-herpesviruses.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31653683 PMCID: PMC6864325 DOI: 10.4049/jimmunol.1900792
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422